STOCKSCOUTER
StockScouter Premium
StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance
Learn more or Get it now! Stockscouter Portfolio performance
ARDS ARIDIS PHARMACEUTICALS INCORPORATED StockScouter® Report
2
StockScouter® Score
ARIDIS PHARMACEUTICALS INCORPORATED, a micro cap growth company in the healthcare sector, is expected to underperform the market over the next six months with higher than average risk
10 is the best possible rating. Learn more.
Summary
Positives
- Earnings growth in the past year has accelerated moderately compared to earnings growth in the past three years. Positive
Concerns
- Moving average analysis for ARDS suggests weak price movement over the medium term. Negative
- The enterprise value-to-sales ratio is higher than the average for comparably-sized companies in the StockScouter universe. Negative
- The multi-period measure of relative price change and consistency is below average. Negative/Neutral
Short-term Outlook
Over the next 1-2 months, StockScouter forecasts that micro cap stocks will be neutral, growth stocks will be neutral, and healthcare stocks will be neutral.
Expected Risk/Return
Core Model Grades
C
C
D
D